Cargando…

Complement system biomarkers in first episode psychosis

Several lines of evidence implicate immunological/inflammatory factors in development of schizophrenia. Complement is a key driver of inflammation, and complement dysregulation causes pathology in many diseases. Here we explored whether complement dysregulation occurred in first episode psychosis (F...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kopczynska, Maja, Zelek, Wioleta, Touchard, Samuel, Gaughran, Fiona, Di Forti, Marta, Mondelli, Valeria, Murray, Robin, O'Donovan, Michael C., Morgan, B. Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Science Publisher B. V 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406022/ https://www.ncbi.nlm.nih.gov/pubmed/29279246 http://dx.doi.org/10.1016/j.schres.2017.12.012

Ejemplares similares

Cortisol and Inflammatory Biomarkers Predict Poor Treatment Response in First Episode Psychosis
por: Mondelli, Valeria, et al.
Publicado: (2015)

T130. ASSOCIATIONS BETWEEN DIFFERENT TYPES OF CHILDHOOD ADVERSITY AND 5-YEAR OUTCOMES IN FIRST-EPISODE PSYCHOSIS PATIENTS
por: Ajnakina, Olesya, et al.
Publicado: (2018)

Serum and gene expression profile of cytokines in first-episode psychosis
por: Di Nicola, Marco, et al.
Publicado: (2013)

T183. LOW LEVELS OF VITAMIN D ARE ASSOCIATED WITH REDUCED CORTICAL THICKNESS AND SURFACE AREA IN FRONTAL, TEMPORAL AND OCCIPITAL REGIONS IN FIRST-EPISODE PSYCHOSIS PATIENTS
por: Ciufolini, Simone, et al.
Publicado: (2020)

S186. THE EFFECTS OF CHILDHOOD TRAUMA ON HIPPOCAMPAL VOLUME IN FIRST EPISODE PSYCHOSIS: DOES CORTISOL PLAY A ROLE?
por: Ciufolini, Simone, et al.
Publicado: (2020)

Monoclonal Antibodies Capable of Inhibiting Complement Downstream of C5 in Multiple Species
por: Zelek, Wioleta M., et al.
Publicado: (2020)

S24. IS IT FEASIBLE TO PREDICT LONG-TERM METABOLIC OUTCOMES IN PSYCHOSIS USING BIOLOGICAL PROFILING AT BASELINE?
por: Iyegbe, Conrad, et al.
Publicado: (2018)

T26. PERINATAL STRESS AND PSYCHOSIS: RESULTS FROM THE BOLOGNA FIRST EPISODE PSYCHOSIS (BO-FEP) STUDY
por: Tarricone, Ilaria, et al.
Publicado: (2018)

Do AKT1, COMT and FAAH influence reports of acute cannabis intoxication experiences in patients with first episode psychosis, controls and young adult cannabis users?
por: Hindocha, Chandni, et al.
Publicado: (2020)

Role of Environmental Confounding in the Association between FKBP5 and First-Episode Psychosis
por: Ajnakina, Olesya, et al.
Publicado: (2014)

White matter integrity as a predictor of response to treatment in first episode psychosis
por: Reis Marques, Tiago, et al.
Publicado: (2014)

Familial risk and childhood adversity interplay in the onset of psychosis
por: Trotta, Antonella, et al.
Publicado: (2015)

A comparison between self-report and interviewer-rated retrospective reports of childhood abuse among individuals with first-episode psychosis and population-based controls
por: Gayer-Anderson, Charlotte, et al.
Publicado: (2020)

A Systematic Review of Cognitive Function in First-Episode Psychosis, Including a Discussion on Childhood Trauma, Stress, and Inflammation
por: Aas, Monica, et al.
Publicado: (2014)

Differential gene expression analysis in blood of first episode psychosis patients
por: Leirer, Daniel J., et al.
Publicado: (2019)

Patterns of illness and care over the 5 years following onset of psychosis in different ethnic groups; the GAP-5 study
por: Ajnakina, Olesya, et al.
Publicado: (2017)

Development and characterization of novel anti‐C5 monoclonal antibodies capable of inhibiting complement in multiple species
por: Zelek, Wioleta M., et al.
Publicado: (2019)

Effect of lifestyle, medication and ethnicity on cardiometabolic risk in the year following the first episode of psychosis: prospective cohort study
por: Gaughran, Fiona, et al.
Publicado: (2019)

Impact of Different Childhood Adversities on 1-Year Outcomes of Psychotic Disorder in the Genetics and Psychosis Study
por: Trotta, Antonella, et al.
Publicado: (2016)

Complement and COVID-19: Three years on, what we know, what we don't know, and what we ought to know
por: Zelek, Wioleta M., et al.
Publicado: (2023)

O8.7. COGNITIVE SUBTYPES IN FIRST-EPISODE PSYCHOSIS AND ASSOCIATION TO TREATMENT RESPONSE
por: Russo, Manuela, et al.
Publicado: (2018)

Alzheimer’s disease-associated complement gene variants influence plasma complement protein levels
por: Veteleanu, Aurora, et al.
Publicado: (2023)

Neuroactive Steroids in First-Episode Psychosis: A Role for Progesterone?
por: Belvederi Murri, Martino, et al.
Publicado: (2016)

Effects of freezer storage time on levels of complement biomarkers
por: Morgan, Angharad R., et al.
Publicado: (2017)

Poor medication adherence and risk of relapse associated with continued cannabis use in patients with first-episode psychosis: a prospective analysis
por: Schoeler, Tabea, et al.
Publicado: (2017)

S77. JUMPING TO CONCLUSIONS AND FACIAL EMOTION RECOGNITION IMPAIRMENT IN FIRST EPISODE PSYCHOSIS ACROSS EUROPE
por: Tripoli, Giada, et al.
Publicado: (2018)

Migration history, first episode psychosis and child abuse: Results from the EU-GEI study
por: Tarricone, I., et al.
Publicado: (2021)

Can cognitive insight predict symptom remission in a first episode psychosis cohort?
por: O’Connor, Jennifer A., et al.
Publicado: (2017)

Searching for psychosis: INTREPID (1): systems for detecting untreated and first-episode cases of psychosis in diverse settings
por: Morgan, Craig, et al.
Publicado: (2015)

Characterizing a pH‐switch anti‐C5 antibody as a tool for human and mouse complement C5 purification and cross‐species inhibition of classical and reactive lysis
por: Zelek, Wioleta M., et al.
Publicado: (2018)

Transdiagnostic dimensions of psychopathology at first episode psychosis: findings from the multinational EU-GEI study
por: Quattrone, Diego, et al.
Publicado: (2019)

5.4 BIOLOGICAL AND EPIDEMIOLOGICAL EXAMINATION OF TRANSDIAGNOSTIC AND SPECIFIC SYMPTOM DIMENSIONS AT PSYCHOSIS ONSET: FINDINGS FROM THE EUGEI STUDY
por: Quattrone, Diego, et al.
Publicado: (2018)

White-matter hyperintensities in first-episode psychosis
por: Zanetti, Marcus V., et al.
Publicado: (2008)

Social Disadvantage: Cause or Consequence of Impending Psychosis?
por: Stilo, Simona A., et al.
Publicado: (2013)

Structural Covariance of Cortical Gyrification at Illness Onset in Treatment Resistance: A Longitudinal Study of First-Episode Psychoses
por: Ajnakina, Olesya, et al.
Publicado: (2021)

T14. ASSESSING DIFFERENCES IN INFLAMMATORY MARKERS BETWEEN FIRST EPISODE PSYCHOSIS PATIENTS AND HEALTHY CONTROLS: THE IMPORTANCE OF CONTROLLING FOR CONFOUNDING FACTORS
por: Giordano, Annalisa, et al.
Publicado: (2018)

O2.1. FIRST EPISODE PSYCHOSIS PATIENTS ACROSS EUROPE DIFFER IN INTELLECTUAL QUOTIENT (IQ) AND EXPOSURE TO ENVIRONMENTAL HAZARDS
por: Ferraro, Laura, et al.
Publicado: (2018)

Duration of Untreated Psychosis in First-Episode Psychosis is not Associated With Common Genetic Variants for Major Psychiatric Conditions: Results From the Multi-Center EU-GEI Study
por: Ajnakina, Olesya, et al.
Publicado: (2021)

Globally Efficient Brain Organization and Treatment Response in Psychosis: A Connectomic Study of Gyrification
por: Palaniyappan, Lena, et al.
Publicado: (2016)

T52. COGNITION, METACOGNITION AND SOCIAL COGNITION AFTER A FIRST EPISODE PSYCHOSIS. PRELIMINARY RESULTS FROM A 5-YEAR-FOLLOW-UP STUDY
por: Tripoli, Giada, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_eif945md2bhmbh9j9vruk0e7nt